Literature DB >> 7262631

In vitro studies on cellular and humoral chemotaxis in Crohn's disease using the under agarose gel technique.

R D'Amelio, P Rossi, S Le Moli, R Ricci, S Montano, F Pallone.   

Abstract

The locomotor function of polymorphonuclear cells (cellular chemotaxis) and serum chemotactic activity (humoral chemotaxis) were studied in 51 patients with Crohn's disease using a method of migration under agarose gel. To study cellular chemotaxis patient's polymorphonuclear cells were challenged against normal Zymosan activated serum and humoral chemotaxis was evaluated testing the patient's Zymosan activated serum against normal polymorphonuclear cells. Cellular chemotaxis in the Crohn's disease group was normal (although 30% of the 51 patients had migration values out of the normal range), while humoral chemotaxis was significantly lower in Crohn's disease patients than in the control group. However, the value of humoral chemotaxis in the group of Crohn's disease patients treated with steroids was lower than that of patients not treated, thus accounting for the low mean value observed inthe Crohn's disease-group as a whole. The present results suggest that a defective chemotactic response may occur in some Crohn's disease patients, particularly during steroid treatment. These findings might be related either to a defective generation of complement derived chemotactic factors or to the presence of circulating inhibitors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7262631      PMCID: PMC1419327          DOI: 10.1136/gut.22.7.566

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  C3 metabolism in ulcerative colitis and Crohn's disease.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

2.  Defective leukotaxis in patients with lepromatous leprosy.

Authors:  P A Ward; S Goralnick; W E Bullock
Journal:  J Lab Clin Med       Date:  1976-06

3.  Chemotaxis of polymorphonuclear leukocytes.

Authors:  P A Ward
Journal:  Biochem Pharmacol       Date:  1968-03       Impact factor: 5.858

4.  Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator.

Authors:  P A Ward; J L Berenberg
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

5.  The pathogenesis of Crohn's disease.

Authors:  M Ward
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

6.  Defective neutrophil chemotaxis in hypogammaglobulinemia and selective IgA deficiency.

Authors:  R D'Amelio; P Rossi; S Le Moli; F Aiuti
Journal:  Clin Immunol Immunopathol       Date:  1980-07

7.  Neutrophil dysfunction in Crohn's disease.

Authors:  A W Segal; G Loewi
Journal:  Lancet       Date:  1976-07-31       Impact factor: 79.321

8.  Humoral immune system in inflammatory bowel disease: I. Complement levels.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Gut       Date:  1977-09       Impact factor: 23.059

9.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

10.  The chemosuppression of chemotaxis.

Authors:  P A Ward
Journal:  J Exp Med       Date:  1966-08-01       Impact factor: 14.307

View more
  9 in total

1.  Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement.

Authors:  J Elmgreen; H Both; V Binder
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

2.  Diminished cytochrome b content and toxic oxygen metabolite production in circulating neutrophils from patients with Crohn's disease.

Authors:  J A Solis-Herruzo; B Fernandez; E Vilalta-Castell; M T Muñoz-Yagüe; I Hernandez-Muñoz; M P de la Torre-Merino; J Balsinde
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

Review 3.  Macrophage activation, chronic inflammation and gastrointestinal disease.

Authors:  A R Tanner; M J Arthur; R Wright
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

4.  Polymorphonuclear leukocyte function in ulcerative colitis and Crohn's disease.

Authors:  A P Kirk; J Cason; J N Fordham; K A Brown; D H Goddard; E J Holborow; J E Lennard-Jones
Journal:  Dig Dis Sci       Date:  1983-03       Impact factor: 3.199

5.  Motility of neutrophils and monocytes in Crohn's disease and ulcerative colitis.

Authors:  J M Rhodes; D P Jewell
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

6.  Defective release of C5a related chemo-attractant activity from complement in Crohn's disease.

Authors:  J Elmgreen; A Berkowicz; H Sørensen
Journal:  Gut       Date:  1983-06       Impact factor: 23.059

7.  In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease.

Authors:  S H Saverymuttu; A M Peters; J P Lavender; V S Chadwick; H J Hodgson
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

8.  Partial defect of neutrophil oxidative metabolism in Crohn's disease.

Authors:  H W Verspaget; M A Mieremet-Ooms; I T Weterman; A S Peña
Journal:  Gut       Date:  1984-08       Impact factor: 23.059

9.  High normal serum levels of C3 and C1 inhibitor, two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis.

Authors:  László Bene; George Füst; Béla Fekete; Agota Kovács; Laura Horváth; Zoltán Prohászka; Kata Miklós; Gábor Pálos; Mohamed Daha; Henriette Farkas; Lilian Varga
Journal:  Dig Dis Sci       Date:  2003-06       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.